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Dear Editor,
Aviles et al.1 recently reported on the long-term follow-up of
54 children, who were exposed to chemotherapy during the
ﬁrst trimester of pregnancy. The mothers were diagnosed
with clinically advanced hematological malignancies requiring
urgent treatment and refused abortion procedure or had an
excessive risk of death or complication if abortion was per-
formed. After a median follow up of 20.4 to 25.3 years, no
adverse events were found in the offspring. No congenital,
physical, hematological, neurological, psychological, cardiac,
and chromosomal abnormalities were observed. This is a
unique and important series, because until now, only case
reports have been published on chemotherapy exposure dur-
ing the ﬁrst trimester, with a limited follow-up period.
However, when interpreting these results, two key ques-
tions remain before solid conclusions can be drawn. First, we
lack information that allows us to estimate the risk of terato-
genesis including, developmental stage at exposure, dose,
duration and frequency of drug administration.2 Human
pregnancy can be divided into three developmental stages:
the preimplantation to early postimplantation period (ﬁrst 2
weeks after conception), the embryonic period of organogen-
esis (weeks 3 to 8) and the fetal period (week 9 to term).
Mutations of pluripotent stem cells in the ﬁrst 2 weeks after
conception are lethal, and continuation of pregnancy depends
on the number of surviving stem cells. When enough normal
stem cells remain, the pregnancy can continue to develop
normally, but with signiﬁcant cell damage a miscarriage will
occur—this is the so-called all-or-nothing phenomenon. The
developing embryo is especially vulnerable in the period of
organogenesis, and the heart, neural tube and limbs are most
easily affected. After week 8, the central nervous system, eyes
and genitalia develop further and remain vulnerable.3 The
ﬁrst trimester is usually deﬁned as the ﬁrst 12–14 weeks of
pregnancy and thus covers the entire implantation and
embryogenesis period and a small part of the fetal period.
Second, no congenital malformations were found. The
absence of congenital malformations should be interpreted,
considering the general background risk of 4.1 to 6.9% for
major malformations and 6.5 to 35.8% for minor malforma-
tions in children who were not exposed to chemotherapy in
utero.4–6 It is well-known that use of chemotherapy during the
ﬁrst trimester increases the risk the risk of major malforma-
tions and fetal death.7 Doll et al.8 reviewed 139 cases and found
25% incidence of malformations after ﬁrst trimester exposure
to chemotherapy for multiagent and 17% for single agent expo-
sure. So, can the authors clarify why the incidence of congenital
malformations is signiﬁcantly lower when compared with simi-
lar studies? Four fetuses were lost (two miscarriages and two
stillborns) during the second trimester of pregnancy, could this
have been caused by congenital malformations?
We agree that maternal prognosis is primordial. In certain
cases, treatment needs to start promptly, and chemotherapy
in the ﬁrst trimester does not always lead to major fetal
complications. Nevertheless, the ﬁrst trimester of pregnancy
remains the highest teratogenic risk period and the utmost
amount of caution is warranted. Pros and cons need to be
thoroughly discussed with the patient and her partner before
commencing therapy. We look forward to the reaction of
Dr. Aviles and his team, so that treatment of pregnant
patients with cancer can continue to improve.
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